# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Form8
New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant rel...
Craig-Hallum analyst Chase Knickerbocker maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Buy and lowers the price ta...
Ironwood 2024 Financial Guidance. Ironwood has revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in...
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.02) per share which missed the analyst consensus estima...
First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD. Results up to Day 91 show that apraglutide...